Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | RAF1 | P04049 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900610 | 0.88 | HDAC4 (0.42) | HDAC4IDO1RAF1TLR9TLR7 | |
| SCHEMBL19900769 | 0.88 | HDAC4 (0.46) | HDAC4IDO1TLR9TLR7TLR8 | |
| SCHEMBL19900747 | 0.79 | HDAC4 (0.36) | HDAC4RAF1TLR9TLR7TLR8 | |
| SCHEMBL19900796 | 0.77 | HDAC4 (0.49) | HDAC4IDO1TLR9TLR7TLR8 | |
| SCHEMBL17730140 | 0.76 | IDO1 (0.53) | IDO1KCNH2 | |
| SCHEMBL20555905 | 0.76 | IDO1 (0.53) | IDO1KCNH2 | |
| SCHEMBL21836475 | 0.76 | IDO1 (0.45) | IDO1ALDH1A1GAAL3MBTL1 | |
| SCHEMBL21836477 | 0.76 | IDO1 (0.45) | IDO1ALDH1A1GAAL3MBTL1 | |
| SCHEMBL17730141 | 0.76 | IDO1 (0.53) | IDO1KCNH2 | |
| SCHEMBL21836586 | 0.74 | TLR7 (0.41) | IDO1TLR7NPSR1ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-23 | — | — | US | disclosed |
| EP-3503891-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | Bristol-Myers Squibb Company (US) | 2019-07-03 | — | — | EP | disclosed |
| CN-109843293-A | The inhibitor and its application method of indole amine 2,3-dioxygenase | 百时美施贵宝公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018039512-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | HDAC4 390/4885IDO1 1/4885RAF1 3013/4885 |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | HDAC4 390/4885IDO1 1/4885RAF1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.